2019-09-262019-09-262000ORTEGA, Katia Coelho et al. Verapamil COER-24 180/240mg na hipertensão arterial leve a moderada em dose única diária avaliado pela monitorização ambulatorial da pressão arterial. Arquivos Brasileiros de Cardiologia, São Paulo, v. 74, n. 3, p. 283-290, 2000.0066-782Xe- 1678-4170http://repositorio.bc.ufg.br/handle/ri/18192Objective - To evaluate the anti-hypertensive effecft of verapamil COER-24 180/240 mg in a single dose at bedtime as single therapy in mild to moderate hypertensives. Methods – A multicentric, open, placebo controlled study of 81 hypertensive patients older than 20 years-old followed to 8 weeks. Blood pressure was measured in doctor’s office and by 24h ambulatory monitoring (ABPM). Results – We observed a decreased in systolic and diastolic blood pressure in doctor’s office at 4 th and 8 th weeks. ABPM showed that both systolic, diastolic and mean blood pressure, heart rate and the mean 24-hour blood pressure load decreased after the 8-week treatment. In addition, there was a reduction of the double-product, especially in the morning and 68% of the patients didn’t have any adverse events. Conclusion - The theraphy verapamil COER-24 180/ 240mg in a single dose is useful for mild and moderate hypertensive patients, with significant pressure decrease in both office blood pressure measurements and in the ABPM/24 hours, as well as showing good tolerability.porAcesso AbertoVerapamilMAPAHipertensão arterialVerapamilHypertensionABPMArtigo10.1590/S0066-782X2000000300009